glutathione s-transferase elisa Human pi 1/GSTP1 Kit (Chemiluminescence) Human Glutathione S-Transferase A1 ELISA

The company's current clinical programs include: HG004gene replacement therapy (ODD & RPDD from the US FDA and ODD from EMA) for RPE65 -associated retinal disease (IRD) 'LIGHT' first-in-human trial (NCT06088992) China's first 'STAR' Phase 1/2 multi-national, "master protocol" clinical trial (NCT05906953) HG202 CRISPR/RNA-editing therapy for neovascular age-related macular degeneration (AMD) 'SIGHT-I' first-in-human trial (NCT06031727) World's first CRISPR/RNA editing therapy 'BRIGHT' Phase 1 clinical trial (NCT06623279) HG204 RNA-editing therapy (ODD & RPDD from FDA and ODD by EMA) for MECP2 duplication syndrome World's first CRISPR/RNA-editing 'HERO' for neurodevelopment disorders first-in-human trial (NCT06615206) HG302 DNA-editing therapy (ODD & RPDD from FDA) for Duchenne muscular dystrophy (DMD) World's first CRISPR/DNA-editing 'MUSCLE' first-in-human trial (NCT06594094) The preclinical pipelines are advancing simultaneously in HG303 CRISPR/DNA-editing for ALS and CRISPR/RNA-editing therapy for Alzheimer's and Huntington's Disease

Rubs in so easily and isnt too thick or pasty like most other face sunscreens

2018;33(106177):e6

56 DasL.ParbinS.PradhanN.KausarC.PatraS